Micron Technology
MU
NVIDIA
NVDA
Adobe
ADBE
Tesla
TSLA
Netflix
NFLX
US Stock MarketDetailed Quotes
GBIO Generation Bio
- 0.480
- -0.032-6.25%
Close Mar 14 16:00 ET
- 0.490
- +0.010+2.08%
Post 20:01 ET
32.16MMarket Cap-0.24P/E (TTM)
0.524High0.480Low944.77KVolume0.510Open0.512Pre Close468.57KTurnover1.94%Turnover RatioLossP/E (Static)67.01MShares4.65052wk High0.37P/B23.42MFloat Cap0.47252wk Low--Dividend TTM48.78MShs Float55.720Historical High--Div YieldTTM8.67%Amplitude0.472Historical Low0.495Avg Price1Lot Size
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Generation Bio Stock Forum
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If yo...
Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases
Monday, 6th January at 4:30 pm
•Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivo
•Programs to focus on silencing hard-to-drug targets of high therapeutic value in T cell-driven autoimmune diseases
•Company reorganization supports evolution of ctLNP-enabled strategy and b...
NEWS
Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting
Positive
Generation Bio's presentation at the ASGCT highlights significant advancements in iqDNA technology and ctLNP delivery systems, showcasing the company's commitment to innovation in genetic medicine.
The rapid enzymatic synthesis process utilized by Generation Bio enhances the performance of iqDNA, providing a potential breakthrough in ...
No comment yet